<DOC>
	<DOCNO>NCT00069888</DOCNO>
	<brief_summary>This clinical trial design study whether docetaxel ( Taxotere ) help reduce risk relapse patient prostate cancer prostate remove surgery , high risk cancer recur . During trial , doctor also closely monitor patient side effect chemotherapy . Docetaxel chemotherapy drug prevents tumor cell divide , stop grow die . Doctors use docetaxel treat lung breast cancer , study show help shrink tumor patient prostate cancer spread part body . The researcher conduct study want determine docetaxel also help reduce likelihood prostate cancer return surgery remove original tumor . All study participant receive 18 dos docetaxel , administer needle insert vein . Each round treatment consist 30-minute , weekly infusion three consecutive week , follow one week chemotherapy . Before chemotherapy , patient take dexamethasone , oral steroid reduces risk allergic reaction medication . If side effect treatment become intense , doctor may modify , delay , even stop chemotherapy trial .</brief_summary>
	<brief_title>A Phase II Trial Adjuvant Docetaxel Patients At High Risk Relapse Following Prostatectomy</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>INCLUSION CRITERIA : patient prostate cancer undergone prostatectomy , high risk cancer recur ( High risk define least 50 percent chance cancer return within three year surgery . ) EXCLUSION CRITERIA : Prior systemic treatment prostate cancer hormonal therapy , chemotherapy , anticancer therapy . Prior radiation therapy Patients receive concurrent therapy cancer . This include alternative therapy Patients require concurrent treatment corticosteroid , exception inhale topical corticosteroid . History malignancy prostate cancer Peripheral neuropathy &gt; /= Grade 2 Psychological , familial , sociological geographical condition permit treatment and/or medical followup require comply study protocol Patients history hypersensitivity reaction product contain Polysorbate 80 ( Tween 80 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>